Quercis Pharma AG is leveraging its novel antithrombotic platform to deliver innovative, safe, and broadly accessible treatments to patients with potentially life-threatening conditions.
Our focus is on prevention of venous thrombosis and pulmonary embolism in high risk cancer patients with our drug candidate ISQ950AN, containing our patented Isoquercetin formulation.
The safety of our investigational drug has been proven in various studies, with no serious side effects having been identified, in particular our drug shows no increased bleeding risk.
A clinical Phase 2 study has shown that ISQ950AN reduced hypercoagulability in cancer patients at high risk for thrombosis with an improved benefit/risk ratio.
Our novel pathway is based on a new mechanism of action, in order to arrest and/or reverse platelet aggregation with a profile that conveys vastly lowered bleeding risk compared to current standard of care.
We control both the raw material production and the Active Performance Ingredient (API) manufacture for our investigational drug ISQ950AN through our subsidiary Quercegen Pharmaceuticals LLC., making Quercis the world’s biggest manufacturer and distributor of pure Quercetin that is GRAS (“Generally Recognized As Safe” by FDA).
The humanitarian aspect of the Company is to look at global disease dangers in less privileged populations and to work with Governments and NGOs to improve healthcare in countries where they find it difficult to pay for development or production of new drugs to combat critical health threats (such as Ebola and Zika Viruses).
Results from Phase 2 study on VTE prevention in cancer – the author’s take
Isoquercetin (ISQ950AN) patented formulation
Isoquercetin prevents platelet activation and initiation of the thrombotic cascade.
Over 20’000 publications referencing Isoquercetin and Quercetin in multiple indications
Safety profile of our main investigational drug is well established; does not cause bleeding – a significant advantage over Heparins and Direct Oral Anticoagulants
Lead indication: VTE prevention in cancer
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality among patients with cancer.
Besides increased risk of VTE, advanced cancer patients have a significantly increased bleeding risk.
Major bleeds are a side effect of today’s anti-coagulants (ACs).
As a result, Venous thromboembolism (VTE) prevention remains limited for advanced cancer patients, despite these patients being at a high risk of VTE.
Currently, anticoagulant use is not recommended prophylactically to cancer patients due to significantly increased bleeding risk.
Quercis’ drug is expected to prevent VTE effectively without increased risk of bleeding.
Other high-priority indication: COVID-19
Evidence of Quercis’ drug candidate ISQ950AN being effective against a variety of virus infections (COVID-19, Influenza, HCV, hRSV, Rhinovirus, Ebola, HIV, etc).
Most patients with severe COVID-19 experience high levels of the D-dimer biomarker that underline higher risks of various forms of thrombosis particularly in the lungs. ISQ950AN’s capacity to inhibit thrombosis and decrease D-dimers in other context may prevent the life-threatening thrombotic events seen in these patients.
Various governments have requested collaboration and several Phase III trials are being prepared
Other advanced indications (Phase II trials)
Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Treatment of Sickle Cell Disease (SCD)
Treatment of Amyotrophic Lateral Sclerosis (ALS) – clearly orphan disease
Treatment of thrombi
Reduction of tumor metastasis
Prevention and treatment of viral diseases
Scientific Advisory Board
Dr. Jean Pierre Bizzari
Chairperson of the Scientific Advisory Board
Dr Jean-Pierre Bizzari is a world-renowned oncology expert with over 35 years of broad experience in oncology drug development. He is former CMO of Celgene where he presided over the registration of drugs including Abraxane, the frontline therapy for pancreatic cancer, Revilimid, Vidaza, Istodax, and Taxotere. Dr. Bizzari is a member of the European Organization of Research and Treatment of Cancer (EORTC), Chairman of EORTC’s New Drug Advisory Committee, and a member of the Scientific Advisory Board of the French National Cancer Institute. He is Professor emeritus of Pathology at Harvard Medical School, and he was a member of National Institute of Health (NIH) expert panels, and of the medical Board of the American Asthma Foundation in the USA.
Dr. Robert Flaumenhaft
Member of the Scientific Advisory Board
Dr Flaumenhaft is Division Chief of Hemostasis and Thrombosis and Professor at Harvard Medical School. Dr Flaumenhaft’s laboratory has subsequently made major contributions to the understanding of the mechanism of platelet granule release and its role in thrombus formation. He holds dual board qualifications from the American Board of Internal Medicine.
Dr. Louis Barbeito
Member of the Scientific Advisory Board
Dr Barbeito is a former director of the Pasteur Institute in Uruguay. He directs the Laboratory of Neurodegeneration at Pasteur, Montevideo and performs research on the cellular and molecular mechanisms of brain aging.
Dr. Manuel Hildalgo
Member of the Scientific Advisory Board
Dr Hidalgo is a world renowned oncologist and specialist in pancreatic cancer. He is Professor of Medicine at Cornell Medical School and Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center. He also is Deputy Associate Director for Clinical Sciences at the Dana-Farber, Harvard Cancer Center, and a Member of the Board of PANCAN. He has authored more than 220 articles in top tier peer-reviewed journals.
Ilias joined Quercis Pharma AG in 2019 coming from Cevian Capital, Europe’s largest active ownership fund. For the last twelve years he was a Partner and Managing Director at Cevian. Before he had been with McKinsey and Company for seven years. Ilias holds a Master of Science in Business Engineering from ETH Zurich, a Ph.D. in Corporate Finance from the University of Zurich, and a Certificate in Corporate Governance form INSEAD.
Jeffrey is the Primary Investigator of various of Quercis’ clinical trials, in particular for the lead indication of VTE prevention in cancer. He is a Professor of Medicine at Harvard Medical School and Chief of the Section of Benign Hematology at Beth Israel Deaconess Medical Center. His research is focused on novel risk factors and therapeutic approaches to thrombotic diseases with an emphasis on cancer associated thrombosis.
Thomas founded Quercis and its predecessor company Quercegen Pharmaceuticals, which acquired the Merck Natural Products Division 2009. He has been the driving force behind the successful development of Quercis’ drug development program. Thomas is a serial entrepreneur, scientist and successful inventor, who has registered multiple drug patents and trademarks. He is the world’s leading expert on naturally occurring small molecules as disease prevention agents with a specific emphasis on Flavonoids.
Dr Jean-Pierre Bizzari is a world-renowned oncology expert with over 35 years of broad experience in oncology drug development. He is former CMO of Celgene where he presided over the registration of drugs including Abraxane, the frontline therapy for pancreatic cancer, Revilimid, Vidaza, Istodax, and Taxotere. He is Professor emeritus of Pathology at Harvard Medical School, and he was a member of National Institute of Health (NIH) expert panels, and of the medical Board of the American Asthma Foundation in the USA. In addition, he was Chairman of Celgene's hematology oncology development committee and a member of its management committee.
Philippe is the former French Minister for Health, a former member of the European Parliament and a United Nations official who has served as Under-Secretary-General of the United Nations and chairman of UNITAID. He studied medicine in Toulouse, became Professor of Medicine at Toulouse Sciences University in 1988, and since 2016, he has also been a visiting Professor at the Harvard T.H. Chan School of Public Health.
Stefan has over 35 years experience in the pharmaceutical and biotech industry. Most recently he was Chief Medical Officer and Head of R&D at Vifor Pharma with responsibility for preclinical and clinical R&D, regulatory and medical affairs as well as drug safety. Prior to that he was Head of Clinical Research at Novartis OTC and worked 20 years at Bayer in R&D. He is the founder of two start-up companies in the oncology area. Stefan holds a Medical Doctor’s degree from the University of Düsseldorf, Germany.
Jean-Pierre is Professor of Pathology at Harvard Medical School. He is also a member of National Institute of Health (NIH) expert panels, and of the medical Board of the American Asthma Foundation in the USA. He is one of the most prominent immunology experts worldwide, the founder of two biotech companies, and a board member of several other biotech companies in Europe.
Mukesh has been involved in more than 100 multi-national clinical trials, and has made hundreds of submissions to the US FDA, EMA, and regulators in more than 40 countries. He has led numerous teams for development of pharmaceutical, biotech and medical device products all the way from early stage development to commercial markets. He authors a popular Weekly Newsletter on FDA related issues read by more than 100,000 readers worldwide.